title: From low- to high-throughput analysis.
abstract: The high throughput is routinely used for the first steps of drug development such as drug discovery screening and toxicity. However, for PK analysis of regulated studies, the requirements and difficulties to achieve high-throughput analysis are more demanding due to regulatory guidelines that are not needed for early steps of drug discovery. High-throughput analysis can be required for any drug type from small molecules to larger ones. Contract research organizations must be prepared to deliver the results associated to these studies in a fast turnaround. Herein, we will describe the challenges encountered by a laboratory in order to go from low- to high-throughput analysis.
authors.affiliation: inVentiv Health Clinical, Québec, Canada.
authors.forename: Ann
authors.initials: A
authors.lastname: Lévesque
authors.affiliation: inVentiv Health Clinical, Québec, Canada.
authors.forename: Sofi
authors.initials: S
authors.lastname: Gagnon-Carignan
authors.affiliation: inVentiv Health Clinical, Québec, Canada.
authors.forename: Sylvain
authors.initials: S
authors.lastname: Lachance
mesh_terms: D055808:Drug Discovery / Q000379:methods*; D057166:High-Throughput Screening Assays / Q000379:methods*; D006801:Humans